R. Feld

1.3k total citations
36 papers, 926 citations indexed

About

R. Feld is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, R. Feld has authored 36 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 11 papers in Epidemiology. Recurrent topics in R. Feld's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (15 papers) and Neuroendocrine Tumor Research Advances (7 papers). R. Feld is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (15 papers) and Neuroendocrine Tumor Research Advances (7 papers). R. Feld collaborates with scholars based in Canada, United States and New Zealand. R. Feld's co-authors include William K. Evans, Robert J. Ginsberg, Yvon Cormier, the Microbiological Reporting Syste of Catalonia Study Group, Larry Rubinstein, F. Shepherd, Joseph L. Pater, Jean-Pierre Ayoub, Salomon Minkin and Pierre Ruffiè and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

R. Feld

33 papers receiving 884 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Feld Canada 11 652 403 176 92 71 36 926
Johanna N. Spaans Canada 14 342 0.5× 277 0.7× 140 0.8× 51 0.6× 144 2.0× 35 844
Svante Bergdahl Sweden 16 1.1k 1.7× 323 0.8× 111 0.6× 71 0.8× 69 1.0× 25 1.3k
S. Harrison United States 20 537 0.8× 279 0.7× 238 1.4× 105 1.1× 86 1.2× 90 984
Jeroen Mebis Belgium 19 261 0.4× 448 1.1× 119 0.7× 320 3.5× 102 1.4× 65 973
Anthony T. Corcoran United States 17 494 0.8× 120 0.3× 85 0.5× 74 0.8× 127 1.8× 32 866
Colin T. Murphy United States 12 324 0.5× 299 0.7× 80 0.5× 78 0.8× 27 0.4× 22 786
Harmien M. Zonderland Netherlands 15 340 0.5× 221 0.5× 96 0.5× 112 1.2× 55 0.8× 24 872
Göran Borghede Sweden 13 408 0.6× 322 0.8× 118 0.7× 66 0.7× 14 0.2× 18 857
Cristina Ivanescu United States 14 659 1.0× 370 0.9× 93 0.5× 187 2.0× 141 2.0× 71 1.0k
Vikas Ostwal India 17 375 0.6× 569 1.4× 167 0.9× 44 0.5× 42 0.6× 146 991

Countries citing papers authored by R. Feld

Since Specialization
Citations

This map shows the geographic impact of R. Feld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Feld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Feld more than expected).

Fields of papers citing papers by R. Feld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Feld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Feld. The network helps show where R. Feld may publish in the future.

Co-authorship network of co-authors of R. Feld

This figure shows the co-authorship network connecting the top 25 collaborators of R. Feld. A scholar is included among the top collaborators of R. Feld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Feld. R. Feld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arriagada, R., Joseph R. Bertino, R. Feld, et al.. (2015). Consensus Report on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 41. 232–241.
2.
Hasani, Arman, et al.. (2011). Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada.. Journal of Clinical Oncology. 29(15_suppl). 7085–7085. 1 indexed citations
3.
Leighl, Natasha B., et al.. (2006). Compliance of adjuvant chemotherapy in non-small cell lung cancer (NSCLC); No longer an issue. Journal of Clinical Oncology. 24(18_suppl). 7154–7154. 1 indexed citations
4.
Feld, R., et al.. (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a clinical practice guideline. 3 indexed citations
5.
Winston, D. J., Hillard M. Lazarus, Roy Beveridge, et al.. (2001). Randomized, Double-Blind, Multicenter Trial Comparing Clinafloxacin with Imipenem as Empirical Monotherapy for Febrile Granulocytopenic Patients. Clinical Infectious Diseases. 32(3). 381–390. 37 indexed citations
6.
Quon, Harry, Frances A. Shepherd, David G. Payne, et al.. (1999). The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 43(1). 39–45. 76 indexed citations
7.
8.
Siu, L.L., Frances A. Shepherd, Nevin Murray, et al.. (1996). Influence of age in the treatment of limited-stage small-cell lung cancer. Pneumologie. 50(7). 1 indexed citations
9.
Shepherd, Frances A., et al.. (1996). Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.. PubMed. 23(5 Suppl 10). 48–54. 8 indexed citations
10.
Feld, R. & Uri Sagman. (1995). Prognostic factors in small cell lung cancer. Seminars in Radiation Oncology. 5(1). 27–32. 7 indexed citations
11.
Feld, R., et al.. (1993). Adjuvant Chemotherapy With Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Completely Resected Stage I Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 85(4). 299–306. 130 indexed citations
12.
Reisinger, Susan A., et al.. (1993). Preoperative radiation therapy in clinical stage II endometrial carcinoma. International Journal of Gynecology & Obstetrics. 40(2). 181–181. 1 indexed citations
13.
Shepherd, Frances A., Robert J. Ginsberg, G. Alexander Patterson, et al.. (1991). Is there ever a role for salvage operations in limited small-cell lung cancer?. Journal of Thoracic and Cardiovascular Surgery. 101(2). 196–200. 71 indexed citations
14.
15.
Biran, Haim, R. Feld, Uri Sagman, et al.. (1989). Carcinoembryonic Antigen, Arginine Vasopressin and Calcitonin as Markers of Early Small-Cell Lung Cancer Relapse. Tumor Biology. 10(5). 258–267. 8 indexed citations
16.
Feld, R.. (1989). Quality of Life Assessment in Patients with Carcinoma of the Lung. CHEST Journal. 96(1). 105S–107S. 4 indexed citations
17.
Ruffiè, Pierre, R. Feld, Salomon Minkin, et al.. (1989). Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.. Journal of Clinical Oncology. 7(8). 1157–1168. 274 indexed citations
18.
Goodwin, Pamela J., R. Feld, W.K. Evans, & Joseph L. Pater. (1988). Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.. Journal of Clinical Oncology. 6(10). 1537–1547. 77 indexed citations
19.
Rusthoven, James J., et al.. (1988). Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster. Cancer. 62(8). 1641–1646. 30 indexed citations
20.
Evans, William K., Frances A. Shepherd, R. Feld, David Osoba, & George Deboer. (1986). First-line therapy with VP-16 and cisplatin for small-cell lung cancer.. PubMed. 13(3 Suppl 3). 17–23. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johanna N. Spaans Breakdown of academic impact, for papers by Svante Bergdahl Breakdown of academic impact, for papers by S. Harrison Breakdown of academic impact, for papers by Jeroen Mebis Breakdown of academic impact, for papers by Anthony T. Corcoran Breakdown of academic impact, for papers by Colin T. Murphy Breakdown of academic impact, for papers by Harmien M. Zonderland Breakdown of academic impact, for papers by Göran Borghede Breakdown of academic impact, for papers by Cristina Ivanescu Breakdown of academic impact, for papers by Vikas Ostwal
Rankless by CCL
2026